Vol. 34 No. 3 (2019): Revista Uruguaya de Cardiología
Cartas científicas

Cardiovascular toxicity by rivastigmine transdermal patches. Two case report

  • Dr. Carolina Juanena,
  • Dr. Darío Pose,
  • Dr. Gustavo Sosa,
  • Federico Pose,
  • Dr. Martín Balzani,
  • Dr. Valeria Senattore,
Dr. Carolina Juanena
Departamento de Toxicología, Centro de Información y Asesoramiento Toxicológico (CIAT), Hospital de Clínicas. Montevideo, Uruguay
Dr. Darío Pose
Departamento de Toxicología, Centro de Información y Asesoramiento Toxicológico (CIAT), Hospital de Clínicas. Montevideo, Uruguay
Dr. Gustavo Sosa
Centro de Terapia Intensiva, Asociación Médica de San José. San José, Uruguay
Federico Pose
Departamento de Toxicología, Centro de Información y Asesoramiento Toxicológico (CIAT), Hospital de Clínicas. Montevideo, Uruguay
Dr. Martín Balzani
Centro de Terapia Intensiva, Asociación Médica de San José. San José, Uruguay
Dr. Valeria Senattore
Servicio de Emergencia, Asociación Médica de San José. San José, Uruguay
Published 25-11-2019

Keywords:

RIVASTIGMINE, ARRHYTHMIAS, CARDIAC, CHOLINESTERASES

Abstract

Rivastigmine, an anticholinesterase drug, improves cholinergic neurotransmission and is used in the treatment of Alzheimer’s and Parkinson’s diseases. In the Center for Information and Toxicological Advice there have been cases of intoxication due to the use of transdermal rivastigmine patches, which have increased in recent times. We present two clinical cases of acute intoxication by transdermal patches of rivastigmine in which serious cardiac arrhythmias were found, associating a decrease in plasma cholinesterase. The risks of the use of this medication are highlighted in order to be attentive to the first symptoms of intoxication, to be able to act timely and to prevent new events.

PDF (Español (España))